Study Exposes Why Most Women Buy Wrong Period Pain Relief — Markets Are Watching

July 2, 2026 4 min read

Millions of women worldwide are spending money on period pain relief products that may not address their specific symptoms effectively. A new analysis of over-the-counter pain medications reveals a significant gap between what women typically purchase and what actually works for different types of menstrual discomfort. The findings carry immediate implications for pharmaceutical manufacturers, retailers, and investors in the consumer health sector.

The Science Behind the Mismatch

Researchers examined data from clinical trials comparing non-steroidal anti-inflammatory drugs (NSAIDs) against paracetamol for menstrual pain relief. The results showed NSAIDs reduced pain intensity by approximately 40 percent more than paracetamol in cases involving moderate to severe cramping. Yet consumer purchasing data indicates that paracetamol-based products account for nearly 35 percent of all period pain relief sales globally. This disconnect represents both a public health concern and a market inefficiency that companies have yet to resolve.

Why Misaligned Products Dominate Shelves

Pharmaceutical analyst Priya Mehta at Berenberg in London explained that marketing budgets heavily influence which products women reach for first. "Brand recognition drives initial purchase decisions more than clinical efficacy in this category," Mehta noted. "Companies spend significantly more on advertising familiar pain relief brands than on educating consumers about ingredient differences." Major retailers in the United Kingdom, including Boots and Superdrug, report that paracetamol-based period products occupy prominent shelf space precisely because of established brand relationships with consumers.

Price Sensitivity and Consumer Behaviour

Research from the University of Manchester found that women aged 18 to 34 were 60 percent more likely to choose generic paracetamol for period pain because of lower price points compared to ibuprofen-based alternatives. Generic NSAIDs typically cost between 20 and 30 percent less than branded NSAIDs. This price-driven behaviour means many women effectively spend more over time on products that provide less relief per dose, creating inefficiencies in household healthcare spending.

Market Size and Investment Implications

The global market for menstrual pain relief products reached an estimated $8.2 billion in 2023, according to Euromonitor International. The sector grows at approximately 4.5 percent annually, outpacing overall consumer health growth. Investment analysts have taken notice. Credit Suisse published a note last month identifying period pain relief as an "overlooked growth category" within consumer pharmaceuticals, citing limited innovation compared to other pain management segments.

Retailer Strategies and Shelf Dynamics

Major supermarket chains across the United Kingdom control significant floor space allocation for pain relief products. Tesco, Asda, and Sainsbury's determine which formulations appear at eye level based on margin data rather than efficacy information. A pharmacist at an independent Boots store in Manchester's Northern Quarter, who asked not to be named, said customers frequently request paracetamol for period pain "because their mothers gave them the same thing." Retail buyers acknowledge that this brand loyalty creates predictable revenue streams but may not serve consumer interests optimally.

What This Means for Manufacturers

For pharmaceutical companies, the research highlights an opportunity. Firms that invest in consumer education about ingredient selection could capture market share from competitors relying on established branding alone. Johnson & Johnson, which manufactures the widely sold Neutrogena and Tylenol brands, declined to comment on its period pain relief strategy. Bayer, the maker of Aspirin and Aleve, has previously marketed NSAIDs specifically for menstrual pain in continental Europe but has not extended those campaigns to British markets.

Regulatory Landscape and Future Outlook

The Medicines and Healthcare products Regulatory Agency (MHRA) does not require over-the-counter pain relief products to specify menstrual pain as a primary indication unless they undergo formal licensing for that use. Consumer groups have lobbied for clearer labelling requirements, arguing that women deserve to understand which ingredients address inflammation-related cramping versus general aches. The MHRA indicated in a statement that it "continuously reviews" guidance on over-the-counter pain product labelling but has not announced specific reforms for period pain disclosures.

Looking Ahead

Healthcare investors should watch for potential shifts in regulatory requirements that could force manufacturers to provide clearer efficacy data for menstrual pain applications. A public consultation expected from the MHRA in the first quarter of 2025 may address labelling standards for over-the-counter analgesics. Consumer advocacy groups plan to present the clinical data on NSAID efficacy for menstrual cramps to regulators in coming months, setting the stage for possible changes that would reshape how pain relief products are marketed and positioned in the $8.2 billion global market.